SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Dr...
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal...
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio o...
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory...
* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in th...
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Prod...
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation ...
SHANGHAI, Sept. 10, 2023 /PRNewswire/ -- Dizal today announced the publication of the Phase I clini...
* Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first C...
* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctD...
SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncolog...
Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presenta...
SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Dr...
* The confirmed objective response (cORR), as assessed by blinded independent central review (BIC...
PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data f...
Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion ...
SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing ph...
SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), tod...